Cliff Hampton, MD
Neurology · Coeur D Alene, IDNPI 1821397118
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.8% of the total across 67 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $573 and has fallen 61.9% since, to $218 in 2025. That places this record below the midpoint for neurology clinicians in ID, where the typical reported total is $1,243.
Across 67 payments — averaging $20.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuropace, Inc.$308
- Livanova USA, Inc.$156
- Sunovion Pharmaceuticals Inc.$132
- Greenwich Biosciences, Inc.$125
- Acorda Therapeutics, Inc$119
- AbbVie$83
- plus $474 from 15 others
What the payments were for
- Speaking & faculty fees$1017%
- Food & beverage$1,28292%
- Education$131%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neuropace, Inc. | 3 | $308 |
| Livanova USA, Inc. | 9 | $156 |
| Sunovion Pharmaceuticals Inc. | 15 | $132 |
| Greenwich Biosciences, Inc. | 1 | $125 |
| Acorda Therapeutics, Inc | 6 | $119 |
| AbbVie(2 entities) | 4 | $83 |
| Novartis | 5 | $72 |
| Lilly USA, LLC | 3 | $54 |
| Biogen | 3 | $54 |
| Jazz Pharmaceuticals Inc. | 3 | $47 |
| Supernus Pharmaceuticals, Inc. | 2 | $38 |
| AstraZeneca | 2 | $37 |
| Sumitomo Pharma America, Inc. | 3 | $26 |
| Boston Scientific | 1 | $25 |
| Kyowa Kirin, Inc. | 1 | $23 |
| SK Life Science, Inc. | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| UCB, Inc. | 1 | $16 |
| Medtronic | 1 | $15 |
| Neurelis, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epidiolex$125
- RNS Neurostimulator Kit$122
How this compares
$1,397 in reported general payments places this provider in the 50th percentile of 59 neurology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 158 | $248,096 |
| AptiomEslicarbazepine Acetate | 66 | $157,098 |
| BriviactBrivaracetam | 78 | $110,321 |
| EpidiolexCannabidiol (Cbd) | 25 | $102,878 |
| Lamotrigine ErLamotrigine | 131 | $87,212 |
| Lacosamide | 467 | $75,437 |
| Emgality PenGalcanezumab-Gnlm | 91 | $71,271 |
| Nurtec OdtRimegepant Sulfate | 22 | $37,364 |
| VimpatLacosamide | 20 | $36,875 |
| ValtocoDiazepam | 42 | $30,743 |
| Oxtellar XrOxcarbazepine | 19 | $30,394 |
| Aimovig AutoinjectorErenumab-Aooe | 31 | $28,510 |
| FycompaPerampanel | 18 | $24,010 |
| Topiramate ErTopiramate | 33 | $22,002 |
| Levetiracetam ErLevetiracetam | 210 | $19,038 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SK Life Science, Inc.Xcopri | $20 | $248,096158 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $132 | $157,09866 claims |
| UCB, Inc.Briviact, Vimpat | $16 | $147,19698 claims |
| Neurelis, Inc.Valtoco | $13 | $30,74342 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $38 | $30,39419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 59 neurology providers in Idaho.
Other neurology in Coeur D Alene
- Nina BozinovCoeur D Alene$76K
- Angela PanaCoeur D Alene$37K
- Lizl LaskyCoeur D Alene$1K
- Charles BrittCoeur D Alene$909
- David SchreiberCoeur D Alene$166
- Michah BrasseurCoeur D Alene$146
- Matthew WomeldorffCoeur D Alene$70
- Bradford TalcottIdaho Falls$252K
- Lawrence GreenNampa$193K
- Stephen VincentIdaho Falls$156K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.